A Nanostructured Lipid System to Improve the Oral Bioavailability of Ruthenium(II) Complexes for the Treatment of Infections Caused by Mycobacterium tuberculosis

Patricia B. da Silva1*, Eduardo Sinésio de Freitas1, Mariana Cristina Solcia1, Paula Carolina de Souza1, Monize Martins da Silva2, Alzir Azevedo Batista2, Carlos E. Eismann3, Ana Marta C. M. Rolisola3, Amauri A. Menegário3, Rosilene Fressatti Cardoso4, Marlus Chorilli1 and Fernando R. Pavan1*

1 School of Pharmaceutical Sciences, Universidade Estadual Paulista, Araraquara, Brazil, 2 Department of Chemistry, Universidade Federal de São Carlos, São Carlos, Brazil, 3 Environmental Studies Center, Universidade Estadual Paulista, Rio Claro, Brazil, 4 Department of Clinical Analysis and Biomedicine, State University of Maringá, Maringá, Brazil

Tuberculosis (TB) is an infectious, airborne disease caused by the bacterium Mycobacterium tuberculosis that mainly affects the lungs. Fortunately, tuberculosis is a curable disease, and in recent years, death rates for this disease have decreased. However, the existence of antibiotic-resistant strains and the occurrence of co-infections with human immunodeficiency virus (HIV), have led to increased mortality in recent years. Another area of concern is that one-third of the world’s population is currently infected with M. tuberculosis in its latent state, serving as a potential reservoir for active TB. In an effort to address the failure of current TB drugs, greater attention is being given to the importance of bioinorganic chemistry as an ally in new research into the development of anti-TB drugs. Ruthenium (Ru) is a chemical element that can mimic iron (Fe) in the body. In previous studies involving the following heteroleptic Ru complexes, [Ru(pic)(dppb)(bipy)]PF6 (SCAR1), [Ru(pic)(dppb)(Me-bipy)]PF6 (SCAR2), [Ru(pic)(dppb)(phen)]PF6 (SCAR4), cis-[Ru(pic)(dppe)2]PF6 (SCAR5), and [Ru(pic)(dppe)(phen)]PF6 (SCAR7), we observed excellent anti-TB activity, moderate cell-toxicity, and a lack of oral bioavailability in an in vivo model of these complexes. Therefore, the objective of this study was to evaluate the toxicity and oral bioavailability of these complexes by loading them into a nanostructured lipid system. The nanostructured lipid system was generated using different ratios of surfactant (soybean phosphatidylcholine, Eumulgin®), and sodium oleate), aqueous phase (phosphate buffer with a concentration of 1X and pH 7.4), and oil (cholesterol) to generate a system for the incorporation of Ru(II) compounds. The anti-TB activity of the compounds was determined using a microdilution assay with Resazurin (REMA) against strains of M. tuberculosis H37Rv and clinical isolates resistant. Cytotoxicity assay using J774.A1 cells (ATCC TIB-67) and intra-macrophage activity were performed. The oral bioavailability assay was used to analyze blood collected from female BALB/C mice. Plasma collected from the same mice was analyzed via inductively
INTRODUCTION

*Mycobacterium tuberculosis* is the main causative agent of tuberculosis (TB). TB causes the highest number of deaths worldwide. In 2016, TB caused 1.3 million deaths and 6.3 million new cases of TB were reported worldwide. The standard treatment for TB currently recommended by the World Health Organization (WHO) for susceptible infections is the concomitant use of the following four antibiotics: rifampicin (RFP), ethambutol (ETH), pyrazinamide (PZA), and isoniazid (INH) administered as a single dose daily for 6 months. This therapy, which is known as first-line therapy, can be successful as long as it is maintained for the full 6-month period. This current therapy still long, when it succeeds (World Health Organization [WHO], 2017a).

The long treatment duration together with a variety of associated adverse events, particularly hepatotoxicity (a potential side-effect of all of the antibiotics included in the treatment), often results in the therapy being discontinued by the patient before the end of the 6-month period (Senousy et al., 2010). Discontinuation of therapy can lead to the emergence of resistant strains and therefore treatment of infections caused by these strains will depend on the sensitivity test, and the treatment may take 2 years. Four different types of resistance to anti-tuberculosis drugs have been described in the current literature. Mono-resistance is the ability of an *M. tuberculosis* strain to resist only one of the four drugs included in first-line therapy. In multi-drug-resistance (MDR-TB), *M. tuberculosis* has resistance to both INH and RMP. In XDR-TB resistance, *M. tuberculosis* is able to resist a fluoroquinolone (moxifloxacin, gatifloxacin, or ofloxacin), in addition to INH and RMP. Some strains are also known to be resistant to injectable antimicrobial agents (aminoglycosides) and a fully resistant (TDR-TB) strain has been reported in some countries (Italy, India and Iran) as being resistant to all antimicrobials currently being used to treat TB. However, the existence of this strain has not yet been officially recognized by the WHO (Mali and Morbale, 2016; World Health Organization [WHO], 2017a).

To address the lack of effective antimicrobials to treat TB and the current drawbacks of first-line therapy, the WHO encourages research into the development of new antimicrobials for TB and recommends that the new drugs should have the following characteristics: (1) reduction of the treatment period, (2) activity against resistant strains, (3) activity against non-replicating bacteria, (4) an intra-macrophagic effect, (5) good bioavailability and few adverse events, and (6) be affordable to patients globally (Bhat et al., 2017).

The development of new molecules effective against *M. tuberculosis* has involved all areas of medicinal chemistry. However, in recent years, there has been a steady increase in the number of studies being conducted in the area of bio-inorganic chemistry. These studies aim to develop new anti-mycobacterial compounds that contain metals/metal ions (Viganor et al., 2015). Ruthenium (Ru) is a chemical element that has the ability to mimic iron (Fe) in the human body. It has low toxicity and is able to form stable complexes (Allardyce and Dyson, 2001).

Numerous Ru(II) complexes exhibiting anti-mycobacterial activity against *M. tuberculosis* have been described in the literature. Do Nascimento et al. (2008) synthesized, characterized, and evaluated the anti-*M. tuberculosis* activity of four different Ru(II) complexes containing phosphine and diimine and the ligand HSpymMe$_2$, 4,6-dimethyl-2-mercaptopirymidinide. [Ru(SpymMe$_2$)(dpbb)(N–N)]PF$_6$, N–N = bipy (1) and Me-bipy (2), bipy = 2,2’-bipyridine and Me-bipy = 4,4’-dimethyl-2,2’-bipyridine were cationic complexes. The other complexes were cis-[RuCl$_2$(dpbb)(N–N)], N–N = bipy (3), and Me-bipy (4). The minimum inhibitory concentration (MIC) of Ru complexes 1–4 was 0.78, 0.78, 3.9, and 6.25 µg mL$^{-1}$, respectively. The results demonstrate that the compounds exhibit good anti-mycobacterial activity.

A study by Pavan et al. (2010b) describes the synthesis, characterization, and determination of the MIC against *M. tuberculosis* H$_3$7Rv of three ruthenium(II) phosphine/picolinate, cis-[Ru(pic)(dpmm)$_2$]PF$_6$ (1), cis-[Ru(pic)(dppe)$_2$]PF$_6$ (2), and [Ru(pic)$_2$ (PPh$_3$)$_2$] (3) [pic = 2-pyridinecarboxylate; dpmm = bis(diphenylphosphino)methane; dppe = 1,2-bis(diphenylphosphino)ethane; PPh$_3$ = triphenylphosphine]. MIC values for the complexes 1–3 were 0.78, 0.256, and >50 µg mL$^{-1}$ respectively. These results indicate that these complexes show promise as anti-mycobacterial agents as the data are comparable to those of second-line drugs currently used to treat TB (Collins and Franzblau, 1997).

Ru(II) complexes with hydroxypyridinecarboxylates as ligand: [Ru(2-OHnic)(dpbb)(bipy)]PF$_6$ (1), [Ru(6-OHnic)(dpbb)(bipy)]PF$_6$ (2) and [Ru(3-OHpic)(dpbb)(bipy)]PF$_6$ (3) [dpbb = 1,4 bis(diphenylphosphino)butane, bipy = 2,2’-bipyridine, 2-OHnic = 2-hydroxynicotinic acid, 6-OHnic = 6-hydroxynicotinic acid and 3-OHpic = 3-hydroxypicolinic acid] were evaluated for activity against *M. tuberculosis* H$_3$7Rv ATCC 27294 and cytotoxicity in the VERO CCL-81 cell line. The complexes 1-3 exhibited MIC values of 0.39, 6.3, and 3.1 µg mL$^{-1}$ respectively. They showed no cytotoxicity and therefore had a high selectivity index (SI = IC$_{50}$/MIC) (Barbosa et al., 2015).

A study by Aguai et al. (2015) demonstrated the anti-tubercular activity of Ru(II) INH complexes: trans-[Ru(NH$_3$)$_4$(SO$_2$)(ina)](BF$_4$)$_2$ (1), trans-[Ru(NH$_3$)$_4$(SO$_2$(INH)](BF$_4$)$_2$ (2)
In vitro activities of Ru(II) phosphine/diimine/picolinate complexes ([Ru(pic)(dppb)(bipy)]PF$_6$ (SCAR1), [Ru(pic)(dppb)(Me-bipy)]PF$_6$ (SCAR2), [Ru(pic)(dppb)(phen)]PF$_6$ (SCAR4), cis-[Ru(pic)(dppe)$_2$]PF$_6$ (SCAR5), cis-[RuCl$_2$(dpdb)(bipy)]PF$_6$ (SCAR6) and [Ru(pic)(dppe)(phen)]PF$_6$ (SCAR7) [pic = 2-pyridinecarboxylic acid anion, dppb = 1,4-bis(diphenylphosphino)butane, bipy = bipyridine, Me-bipy = 4,4′-dimethyl-2,2′-bipyridine, phen = 1,10-phenanthroline, dppe = 1,2-bis(diphenylphosphino)ethane] against M. tuberculosis were studied by Pavan et al. (2013). All of the SCAR compounds exhibited anti-M. tuberculosis activity against both susceptible and drug-resistant strains as well as non-replicating, persistent bacteria and showed no toxicity or mutagenicity.

The low solubility of metallic compounds in water makes it impossible to study their biological activity in animals. Therefore, alternatives have been sought for the delivery of metallic compounds using specialized methods that effectively compartmentalize various groups of molecules and modify their behavior in the organism (Sato et al., 2015).

The nanostructured lipid system (NLS) as a microemulsion (ME) is a system that was developed by Hoar and Schulman in 1943. The system is thermodynamically stable and isotropically translucent, and is composed of two immiscible liquids (oil/water) stabilized by an interfacial film of surfactants. The number of pharmaceuticals utilizing novel drug delivery systems has increased significantly in recent years and is expected to increase further (Dos Santos Ramos et al., 2018). There continues to be a strong focus on the design and development of new drug-delivery systems to increase the effectiveness of existing drugs. Recently, a large number of studies have focused on the use of MEs as drug-delivery systems (Ho et al., 1996; Lawrence, 1996), particularly after the discovery of a successful ME for oral use, called Neoral® (Lawrence, 1996). NLSs have a low surface tension. This is an important property that improves the solubility, stability, and bioavailability of molecules loaded into this carrier and thereby enhances absorption and permeability (Dos Santos Ramos et al., 2018).

There are several reports on the methods for enhancing the solubility, and hence the bioavailability, of molecules. Ghosh et al. (2006) developed an NLS, which consisted of non-ionic Labrasol at 32% (as surfactant), Plurisol Oleique at 8% (as cosurfactant), Labrafac at 10%, and water at 50%, with the aim of improving the bioavailability of acyclovir, a poorly soluble drug. The results of an in vivo study showed that the bioavailability of acyclovir improved 12.78 times when it loaded into the NLS following oral administration, compared to that of commercially available acyclovir tablets.

In a study conducted by Hu et al. (2011), in vivo experiments in rats were performed to evaluate the oral bioavailability of ibuprofen loaded into a lipid formulation composed of 17% Labrall M 1944CS, 28% Cremophor RH40/Transcutol P (3:1, w/w), and 55% water and granule formulation. The authors observed that the lipid system rendered the drug, ibuprofen, 1.9 times more bioavailable than its granule formulation.

Curcumin has several pharmacological activities. However, it has low solubility in water. In order to improve the oral bioavailability of the drug, Hu et al. (2012) developed a lipid system containing an oil phase composed of Capyrol 90, with Cremophor RH40 as the surfactant and as a Transcutol P aqueous solution as the co-surfactant. A study in rats using the curcumin-containing formulation showed an improvement in the solubility, and consequently the bioavailability of the drug, which was 22.6 times greater than that of the suspension.

In order to improve the oral bioavailability of feldopidine, Singh et al. (2018) developed an NLS consisting of α-linolenic acid (oil phase), Tween 80 (surfactant), and isopropanol (co-surfactant). The authors observed an improvement of 308.3% in the bioavailability of the developed formulation compared to that of the commercial formulation.

The purpose of this study was to analyze the following five loaded Ru(II) compounds: [Ru(pic)(dppb)(bipy)]PF$_6$ (SCAR1); [Ru(pic)(dppb)(Me-bipy)]PF$_6$ (SCAR2); [Ru(pic)(dppb)(phen)]PF$_6$ (SCAR4), cis-[Ru(pic)(dppe)$_2$]PF$_6$ (SCAR5) and [Ru(pic)(dppe)(phen)]PF$_6$ (SCAR7), [pic = 2-pyridinecarboxylic acid anion, dppb = 1,4-bis(diphenylphosphino)butane, bipy = bipyridine, Me-bipy = 4,4′-dimethyl-2,2′-bipyridine, phen = 1,10-phenanthroline, dppe = 1,2-bis(diphenylphosphino)ethane] into the NLS composed of a 10% oil phase (i.e., cholesterol), 10% surfactant (i.e., soy phosphatidylcholine, sodium oleate, and Eumulgin® HRE 40 [castor oil polyoxyl-40-hydrogenated in a proportion of 3:6:8], and an 80% aqueous phase (i.e., phosphate buffer with a concentration of 1X and pH 7.4) as a strategy to enhance the oral bioavailability. The cytotoxicity of these complexes was evaluated in mouse macrophages (J774A.1 ATCCb TIB-67). Intramacrophage activity was determined using an in vitro infection model using the M. tuberculosis strain H$_{37}$Rv (ATCC 27294), and in vivo oral bioavailability was analyzed using a rapid screening method.

**MATERIALS AND METHODS**

**Inorganic Compounds**

The complexes [Ru(pic)(dppb)(bipy)]PF$_6$ (SCAR1), [Ru(pic)(dppb)(Me-bipy)]PF$_6$ (SCAR2), [Ru(pic)(dppb)(phen)]PF$_6$ (SCAR4), cis-[Ru(pic)(dppe)$_2$]PF$_6$ (SCAR5) and [Ru(pic)(dppe)(phen)]PF$_6$ (SCAR7) were synthesized according to the methodology previously described by our group (Pavan et al., 2011). The structures of the SCARs complexes are shown in Figure 1.

**Nanostructured Lipid System (NLS)**

**NLS Preparation**

The NLS was synthesized as previously described by our group (De Freitas et al., 2014; da Silva et al., 2016) and had the following composition: 10% oil phase (i.e., cholesterol), 10% surfactant (a mixture of soy phosphatidylcholine, sodium oleate, and Eumulgin® HRE 40 [polyoxyl 40 castor oil-hydrogenated]), 3:6:8, and 80% aqueous phase (phosphate buffer with a concentration of 1X and pH 7.4). The NLS was prepared by
the sonication method using rod sonicator with 700 watts of power and 20Hz of frequency (Q700 of QSonica®, Newtown, CT, United States). The mixture was sonicated for 10 cycles of 1 min with 15% amplitude and 30 s intervals between then. The flask containing the mixture was maintained in ice bath throughout the process. At the end of 10 cycles, the NLSs were centrifuged for removing the titanium residues released during the sonication process; The NLSs were synthesized in the previous day (24 h) before of the assays.

Preparation of the SCARs-Loaded Into the NLS
The Ru compounds studied were incorporated as follows:

For \emph{in vitro} experiments, a mass of 5 mg of the respective compound of interest was weighed and solubilized in 1 mL NLS. The solution obtained was sonicated on the rod sonicator with 700 watts of power and 20 Hz of frequency (Q700 of QSonica®, Newtown, CT, United States) for 3 min in a 15% amplitude ice bath for complete incorporation. The sample was then centrifuged to remove the titanium residues from the sonication process and the concentration obtained was 5 mg ml$^{-1}$.

For the \emph{in vivo} experiments, the same methodology of incorporation was performed, however, 10 mg of the respective compound of ruthenium(II) was used for 1 ml NLS, consequently the concentration obtained in the sample was 10 mg ml$^{-1}$, which corresponds to a dose of 300 mg/kg body weight.

Each formulation of NLS was diluted (100 µL sample in 900 µL ultrapure water). All experiments were conducted in triplicate at 25°C and the results were expressed as mean ± standard deviation (mean ± SD).

\textbf{Zeta potential analysis}

The zeta potential of the NLSs was assessed by the electrophoretic mobility of the particles according to the Helmholtz–Smoluchowski equation, and processed using the Zetasizer Nano equipment software NS (Malvern Instruments, San Diego, CA, United States). Each formulation of NLSs was diluted in ultrapure water at a ratio of 1:100. The ZP analysis was performed in triplicate at 25°C and the results were expressed as mean ± S.D.

\textbf{Biological Assays}

\textbf{Determination of \emph{in vitro} Activity Against \textit{M. tuberculosis} H$_{37}$Rv and Resistant Clinical Isolates}

The anti-\textit{M. tuberculosis} activity of the compounds was determined using the Resazurin Microtiter Assay (REMA) method according to Palomino et al. (2002). Stock solutions of the tested compounds were prepared in dimethyl sulfoxide (DMSO), incorporated into the NLS, and diluted in Middlebrook 7H9 broth (Difco, Detroit, MI, United States) supplemented with oleic acid, albumin, dextrose, and catalase (OADC enrichment - BBL/Becton-Dickinson, Detroit, MI, United States) to obtain a final drug concentration range of 0.09–25 µg ml$^{-1}$. A suspension of either the \textit{M. tuberculosis} H$_{37}$Rv ATCC 27294 or the clinical isolate was cultured in Middlebrook 7H9 broth supplemented with OADC and 0.05% Tween 80. The culture was frozen at $-80^\circ$C in aliquots. Two days later, the CFU/ml of the aliquot was determined. The concentration was adjusted to $5 \times 10^5$ CFU/ml, and 100 µl of the inoculum was added to each well of a 96-well
In vitro Cytotoxic Activity

The cytotoxicity of the complexes solubilized in DMSO and loaded into the NLS was measured in mouse macrophages (J774A.1 ATCCb TIB-67) as described by Pavan et al. (2010a). The cells were incubated at 37°C in 5% CO₂ on plates with a surface area of 12.50 cm² in 10 ml RPMI (Vitrocell®, Campinas, SP Brazil) supplemented with 10% fetal bovine serum, gentamicin sulfate (50 mg l⁻¹) and amphotericin B (2 mg l⁻¹). This technique consists of collecting the cells using a scraper, centrifuging (2000 rpm for 5 min), counting the number of cells in a Neubauer chamber, and then adjusting the concentration to 3.4 × 10⁵ cells ml⁻¹ in RPMI. Next, 200 μl suspension was deposited into each well of a 96-well microplate and incubated at 37°C in an atmosphere of 5% CO₂ for 24 h. The medium and any cells that did not adhere, and the plate was then washed and lyzed with 1 ml of sterile distilled water containing 0.1% Triton X–100 per well. The CFU was determined and the percent inhibition by each compound at each concentration was calculated after comparison with the positive control. As a standard test, intracellular inhibition by RFP was determined. Each test was set up in triplicate (Dos Santos Fernandes et al., 2017).

In vivo Oral Bioavailability Assay

Plasma collection for evaluation of oral bioavailability, through pharmacokinetic screening in BALB/c mice

Female, 4–8-weeks old BALB/c mice weighing 15–20 g were purchased from the central animal facilities of Campinas State University (UNICAMP, Campinas, SP, Brazil). The protocol for plasma collection was approved by the Ethics Committee on the Use of Animals in Research – CEUA School of Pharmaceutical Sciences of Araraquara – UNESP (Protocol number 24/2013). The mice were maintained in polycarbonate cages at 23 ± 2°C, 56 ± 2% humidity, in a 12 h light/dark cycle, under specific pathogen-free conditions (in a positive-pressure cabinet), and the animals were provided with food and water ad libitum. The in vivo oral bioavailability of the SCAR complexes, either solubilized in sunflower oil or loaded into the NLS, was determined according to a previously reported method (Gruppo et al., 2006). The animals (n = 4 animals/group) received a dose of 300 mg/kg body weight via oral gavage which corresponds to a concentration 10 mg ml⁻¹ of the complex. The groups studied were SCAR1, SCAR2, SCAR4 and SCAR7 solubilized in sunflower, SCAR1-loaded, SCAR2-loaded, SCAR4-loaded, SCAR5-loaded and SCAR7-loaded into the NLS, the control groups were sunflower and NLS, and negative control that received water. At 20 min, 1, 2, and 4 h following drug administration, blood was drawn from two mice via the retro-orbital vein, draining the sub-mandibular vein and the face of the mice at the point where the origins of the jugular vein join, to allow the collection of drops of blood exuding from the point of penetration (Golde et al., 2005). The plasma was then separated from the blood and stored at −70°C for quantification.

Specimen preparation for inductively coupled plasma mass spectrometry (ICP-MS)

The Ru(II) complexes were quantified using Inductively Coupled Plasma Mass Spectrometry (ICP-MS) X-Series 2 (Thermo Scientific®, Germany) (Batista et al., 2009). Fifty microliters of plasma samples and 5950 μL of bi-distilled nitric acid 20% (v/v) were digested in a microwave (Berghof speedwave D 72800), at 170°C. Following digestion, 2 ml of the samples were transferred to a 15 ml conical tube and 800 μl of the internal standard stock solution (Bi, Ho, In, Li-6, Sc, Tb, Y) was added in order to obtain a
The detection limit (DL) and the quantification limit (QL) of the method were determined by Martincic et al. (2014), by reading the blank of the curve with ten replicates, and by applying the following equations:

\[
DL = 3 \times \text{(Standard deviation of white) } \mu\text{g L}^{-1} \quad (1)
\]

\[
QL = 10 \times \text{(Standard deviation of white) } \mu\text{g L}^{-1} \quad (2)
\]

The in vivo oral bioavailability was determined as the mean of two independent assays.

RESULTS AND DISCUSSION

Some data presented in this paper belong to a master’s dissertation by Eduardo Sinésio de Freitas (Freitas, 2015).

NLS Characterization

Table 1 shows the mean values and standard deviation of particle sizes, PDI and ZP for the NLS and for the coordination compounds loaded into the nanosystem. Looking at the table, the particle size of the NLS was 171.6 ± 0.8 nm. The incorporation of the SCARs compounds induced a small variation in particle size, without exception, ranging from 185.1 ± 0.6 to 213.0 ± 2.5 nm. All values obtained are in the range of 10–200 nm (100–2000 Å), ideal range for NLS (Formariz et al., 2005). When comparing the NLS and the formulations containing the SCARs-loaded into the nanosystem, there was a small increase in the size of the particle diameter, a strong indication that the SCARs were incorporated into the NLS.

The PDI determines the particle size distribution, according to Kumar et al. (2015) PDI values in the range 0.01–0.5 indicate monodisperse particles, whereas PDI values > 0.7 indicate a polydisperse distribution. The PDI values of the NLS and the SCARs-loaded into the NLS were found in the range 0.144 ± 0.012 – 0.258 ± 0.008, which indicated the monodispersity of the formulations.

The zeta potential values obtained in this study were ranged from 0.305 ± 0.089 – 0.581 ± 0.021 mV, practically neutral values and according to the composition of the nanosystem, since the addition of non-ionic surfactants doesn’t affect the surface potential (Bruxel et al., 2012).

Anti-mycobacterial and Cytotoxicity Activities

The in vitro results (i.e., MIC\(_{90}\), IC\(_{50}\), and SI values) for the free Ru(II) compounds and those loaded into the NLS are shown in Table 2.

Analysis of the results presented in Table 2 revealed that the anti-\(M.\) \textit{tuberculosis} activity of the Ru (II) heteroleptic complexes was practically maintained for all incorporated compounds. However, the activity (MIC) statistically better was observed for the SCAR2-loaded, SCAR4-loaded, SCAR5-loaded and SCAR7-loaded complexes into the NLS than for those solubilized in DMSO. While comparing the activity of SCAR1 solubilized in DMSO and loaded into the NLS, no statistical difference was observed. Furthermore, a reduction in toxicity was observed in assays using macrophages for all complexes loaded into the NLS, these results showed that these formulations are statistically less toxic than the complexes solubilized in DMSO. The toxicity of some compounds was found to be reduced by 10-fold, as demonstrated by the values shown under the SI (DMSO/NLS) column; we performed a percentage comparison of the increase in the SI of the nanostructured compounds with that of the compounds solubilized in DMSO. SIs of the complexes loaded into the NLS are statistically better than the SIs of the complexes solubilized in DMSO. It should be noted that the NLS did not show any anti-TB activity. The MIC of the complexes loaded into the NLS increased only slightly. This is likely to be due to the slower release of the complexes of the matrix. In spite of this, the loaded complexes were more selective against \(M.\) \textit{tuberculosis}, in view of the remarkable improvement in IC\(_{50}\) values. These results demonstrate that the NLS is able to reduce the cytotoxicity of Ru (II) complexes as well as maintain anti-TB activity (De Freitas et al., 2014). These results can be explained by the presence of cholesterol in the NLS. As sterol is present in greater quantities in the human body, it was chosen as a component of the system, mainly in order to reduce the toxicity of the complexes loaded into the NLS, as well as to promote interaction with the cell membrane of \(M.\) \textit{tuberculosis}, which is bound by a phospholipid bilayer that facilitates the performance of SCAR compounds (De Freitas et al., 2014).

Anti-mycobacterial Activity of Clinical Isolates

Table 3 shows the results of MIC\(_{90}\) determination using clinical isolates of \(M.\) \textit{tuberculosis} from Clemente Ferreira (CF) hospital between 2007 and 2009 in São Paulo city. The strains used

| Formulation | Mean Diameter ± SD (nm) * | Mean PDI ± SD* | Mean Zeta Potential ± SD (mV) |
|-------------|---------------------------|----------------|------------------------------|
| NLS         | 171.6 ± 0.8               | 0.152 ± 0.014 | 0.395 ± 0.062               |
| SCAR1-loaded| 213.0 ± 2.5               | 0.258 ± 0.008 | 0.305 ± 0.089               |
| SCAR2-loaded| 208.9 ± 2.6               | 0.211 ± 0.008 | 0.581 ± 0.021               |
| SCAR4-loaded| 185.1 ± 0.6               | 0.144 ± 0.012 | 0.318 ± 0.014               |
| SCAR5-loaded| 196.6 ± 0.8               | 0.178 ± 0.008 | 0.402 ± 0.017               |
| SCAR7-loaded| 207.8 ± 2.4               | 0.213 ± 0.008 | 0.406 ± 0.011               |
were 100, 158 and 169. In the determination of MIC90, strains of isolates CF 158 and 169 were resistant to INH and RIF and strain CF 100 showed resistance to INH, being classified with profiles monoresist and resistance MDR-TB. Table 3 also shows the genotypic resistances found by sequencing (previous work) for these strains (Miyata et al., 2011). In determining MIC90 of the SCARs solubilized in DMSO and loaded into the NLS, all complexes showed activity against these drug resistant strains, used in the treatment of TB. Despite the increase in MIC90 values, the strains tested were not resistant to the SCAR complexes, since antimicrobial resistance exhibited expressive values in relation to MIC90 in sensitive bacteria, as observed for the INH and RIF drugs. Of the complexes tested, SCAR4 was the only one that didn’t present statistical differences in the MIC90 values against the strains tested when compared to the compost solubilized in DMSO and loaded into the NLS. Regarding strain 100, only SCAR7 showed statistical differences in the value of MIC90, presenting a better activity of the complex than the one not loaded. Also regarding the action of SCAR7 against the other resistant strains, no statistical differences were observed in MIC90 values. On the activity of the SCAR1, SCAR2 and SCAR5 complexes, statistical differences were demonstrated against strains 158 and 169, in which non-loaded complexes presented better MIC values than the loaded. Once the antimicrobial resistant TB indexes were declared a global threat by the WHO, new molecules that have activity against these strains, represent a great advance in the control and treatment of the disease (World Health Organization [WHO], 2017b).

The SCAR complexes solubilized in DMSO showed promising activity against all of the resistant strains. When the SCARs were loaded into the NLS, they maintained their activity against the CF 100 strain, which is resistant to INH, as well against the 158 and 169 strains, which are resistant to both INH and RIF. The mechanism of action of these Ru (II) complexes has not yet been elucidated. Based on the results of our study, we suggest that the mechanism of action differs from that of the main drugs used in the therapy, INH and RIF.

**Intra-macrophage Activity**

The results obtained from the intra-macrophage activity assay of the SCAR compounds loaded into the NLS, in which the potential of each complex to inhibit the growth of *M. tuberculosis* within macrophages was evaluated, are shown in Figure 2.

From the results of our analysis, we can confirm that the SCARs loaded into the NLS have intra-macrophagic activity as they inhibit the growth of *M. tuberculosis* within macrophages in a concentration-dependent manner, with the exception of SCAR5-loaded into the NLS, which was evaluated only at a concentration (1.56 µg mL⁻¹) due to cytotoxicity against macrophage cells in the 72-h period.

Our results demonstrate that the SCARs loaded into the NLS have intra-macrophagic activity even at MIC, with the exception of SCAR5, which in most cases does not have intra-macrophagic activity as reported in the literature, as it is much more difficult to treat intracellular bacteria due to the need to administer high therapeutic doses in order to reach the intra-macrophagic bacillus (Schwartz et al., 2006).

Although all complexes show increasing percentages of intracellular inhibition as the concentration increases, statistically this characteristic was not found for SCAR2 and SCAR7, demonstrating that even lower concentrations of these complexes are able to effectively inhibit *M. tuberculosis* within macrophages as compared to use of higher concentrations. This fact reveals a potential for SCAR2 and SCAR7 to act against intracellular bacilli more potently than the other SCARs.

For the SCAR4-loaded into the NLS the increase of the concentration of 12.5 µg mL⁻¹ to 50 µg mL⁻¹ also didn’t present significant difference in the intracellular inhibition potential of this complex, thus indicating that from the concentration of 12.5 µg mL⁻¹ the intracellular inhibition remained constant.

**In vivo Oral Bioavailability**

The *in vivo* test of oral bioavailability involves the use of a rapid screen that reveals whether an administered complex or the final product has been absorbed into the bloodstream. Quantification via ICP-MS estimates the concentration of metal ions in the plasma in µg L⁻¹ at a range of time-points following administration of the compounds in the animals by gavage; the inhibitory percentage of the complexes present in the plasma was determined using the REMA technique against *M. tuberculosis* H₃₇Rv. The results of the assay confirm that the compounds are bioavailable in blood (Table 4). Figure 3 shows the time-concentration profile for SCAR 2 loaded into the NLS in

---

**Table 2** | Results of biological assays (MIC₉₀ and IC₉₀) and determination of SI of the Ru(II) compounds and those loaded into the NLS against *M. tuberculosis* H₃₇Rv.

| Identification | Compounds | MIC₉₀ - µg mL⁻¹ | IC₉₀ - µg mL⁻¹ | SI – IC₉₀/MIC₉₀ | SI |
|---------------|-----------|----------------|----------------|-----------------|-----|
|               | DMSO      | NLS            | DMSO           | NLS             |     |
| SCAR1         | [Ru(pic)(dpbb)(bipy)]PF₆ | 1.18 ± 0.08a | 1.37 ± 0.07a  | 22.26 ± 1.85a | 59.64 ± 12.28b | 18.90± 143.50b | 130.2% |
| SCAR2         | [Ru(pic)(dpbb)(Me-bipy)]PF₆ | 1.08 ± 0.12a | 1.88 ± 0.17a  | 6.51 ± 0.67a  | 50.50 ± 1.03b  | 6.02± 26.86b  | 346.2% |
| SCAR4         | [Ru(pic)(dpbb)(phen)]PF₆ | 1.34 ± 0.08a | 1.71 ± 0.17a  | 7.57 ± 0.13a  | 92.31 ± 9.06b | 5.67± 53.99b  | 852%  |
| SCAR5         | cis-[Ru(pic)(dppe)]PF₆ | 1.32 ± 0.03a | 2.93 ± 0.12a  | 3.88 ± 0.98a  | 33.17 ± 1.23b | 2.95± 11.39b  | 284.1% |
| SCAR7         | [Ru(pic)(dppe)(phen)]PF₆ | 0.98 ± 0.05a | 1.71 ± 0.13a  | 14.36 ± 1.57a | 77.89 ± 8.03b | 14.69± 45.56b | 210.2% |

For the MIC₉₀ and IC₉₀, the results are expressed as mean ± standard deviation (mean ± SD). MIC₉₀, the lowest concentration resulting in 90% growth inhibition of *M. tuberculosis*. IC₉₀, the highest concentration of compound inhibiting the growth of at least 50% of the cells. NLS, nanostructured lipid system. SI (DMSO/NLS). Ratio of selectivity indices in DMSO and NLS. Statistical analysis: Prism 7.0, one-way ANOVA – a,b: different lowercase letters on the lines indicate statistical difference by the Tukey’s test (P < 0.05); Equal Licsys do not differ from each other significantly.
TABLE 3 | Phenotype and Genotype Resistance of M. tuberculosis with Phenotypic Resistance Profiles Determined by REMA Methodology and Genotypic Resistance by Sequencing of Genes Initially Detected Based on DNA Polymorphism by PCR-SSCP (Single Strand Conformation-PCR Polymorphism).

| Genotypic profile | Nuc Cod aa | Nucl Cod aa | Scar4-loaded | Scar5-loaded | Scar7-loaded |
|-------------------|------------|-------------|---------------|---------------|---------------|
| Scar1-loaded      | C337 Tyr   | C337 Tyr    | C337 Tyr      | C337 Tyr      | C337 Tyr      |
| Scar2-loaded      | T337 Tyr   | T337 Tyr    | T337 Tyr      | T337 Tyr      | T337 Tyr      |
| Scar3-loaded      | 81 Hys     | 81 Hys      | 81 Hys        | 81 Hys        | 81 Hys        |
| Scar4-loaded      | 81 Hys     | 81 Hys      | 81 Hys        | 81 Hys        | 81 Hys        |
| Scar5-loaded      | 81 Hys     | 81 Hys      | 81 Hys        | 81 Hys        | 81 Hys        |
| Scar6-loaded      | 81 Hys     | 81 Hys      | 81 Hys        | 81 Hys        | 81 Hys        |
| Scar7-loaded      | 81 Hys     | 81 Hys      | 81 Hys        | 81 Hys        | 81 Hys        |

Anti-TB Activity of SCARs Solubilized in DMSO, Loaded into the NLS, and of the Drugs Used in the Therapy Against Clinical Isolates from Clemente Ferreira Hospital CF100, which is Resistant to INH, and Strains CF158 and CF169, which are Resistant to INH and RIF. INH, isoniazid; RIF, rifampicin; Nucl, nucleotide; Cod, codon; aa, amino acid; n.d., not detected; NL, not loaded; L, loaded. MIC, the lowest concentration resulting in 90% growth inhibition of M. tuberculosis. Statistical analysis: Prism 7.0, one-way ANOVA with Tukey’s post-test. Significant differences found between the concentrations of each SCAR loaded compared to its highest concentration tested are indicated by *P < 0.05. The percentage of inhibition was determined as the mean of three independent assays.

FIGURE 2 | Intra-macrophage activity of Scar1-loaded, Scar2-loaded, Scar4-loaded, Scar5-loaded, and Scar7-loaded complexes after infection of J774A.1 macrophages with M. tuberculosis H37Rv (ATCC 27294). Statistical analysis: Prism 5.0, one-way ANOVA with Newman–Keuls post-test. Significant differences found between the concentrations of each SCAR loaded compared to its highest concentration tested are indicated by *P < 0.05. The percentage of inhibition was determined as the mean of three independent assays.

plasma. For Ru quantification, Ru 102 was determined to be the most abundant and having the least interference in the analysis.

The calibration curves used for quantitation of plasma samples showed an R² correlation coefficient of 0.999, and the detection limit (DL) for Ru 102 was 0.0006968 µg L⁻¹. The quantitation limit (QL) was 0.002322 µg L⁻¹. In general, Ru 102 was detected and quantified in the plasma of the animals that received the SCAR complexes loaded into the NLS, whereas it was possible to detect the metal ion (Ru) in these animals. This result indicates that the nanostructured system has the bioavailable compounds.

The plasma concentrations for the SCAR1-loaded complex were 0.796 µg L⁻¹, 8.300 µg L⁻¹, 0.745 µg L⁻¹, and 0.606 µg L⁻¹. Plasma concentrations for the SCAR2-loaded complex were 0.562 µg L⁻¹, 0.6515 µg L⁻¹, 2.168 µg L⁻¹, and 0.5131 µg L⁻¹. Plasma concentrations for the SCAR5-loaded complex were 5.672 µg L⁻¹, 49.40 µg L⁻¹, 14.47 µg L⁻¹, and 6.906 µg L⁻¹, at 20 min, 1, 2, and 4 h following collection, respectively. The concentration of the SCAR1-loaded and SCAR5-loaded complex at 1 h was the Cmax (maximum concentration) observed i.e., 8.300 and 49.40 µg L⁻¹, respectively. For the SCAR2-loaded complex, Cmax in the plasma was achieved after 2 h (2.168 µg L⁻¹), after which it decayed. For the SCAR4-loaded complex, the plasma concentrations were 352.0 µg L⁻¹, 15.25 µg L⁻¹, 7.937 µg L⁻¹, and 5.247 µg L⁻¹, and for the SCAR7-loaded complex, they were 1.455 µg L⁻¹, 0.3577 µg L⁻¹, 0.1598 µg L⁻¹, and 0.09344 µg L⁻¹, for the same respective sampling times. The concentration of the SCAR 4-loaded and SCAR7-loaded complexes at 20 min was already the Cmax observed, indicating that these complexes have a faster absorption than the SCAR1-loaded, SCAR2-loaded, and SCAR5-loaded complexes.

The difference observed by comparing the time profiles of group 1 (SCAR1-loaded, SCAR2-loaded, and SCAR5-loaded complexes) and group 2 (SCAR4-loaded and SCAR7-loaded complexes) is likely to be due to their structural differences with respect to the ligands present in the coordination
TABLE 4 | Plasma levels of the SCAR complexes loaded or not loaded into the NLS following a single oral administration. For the MIC
90 the results are expressed as mean ± standard deviation (mean ± SD) of three
independent assays.

| Compound          | Standard |
|-------------------|----------|
|                   | MIC (μg mL⁻¹) | Pre-determined |
| Scar1-not loaded  | 1.18 ± 0.08 | 300 |
| Scar1-loaded      | 1.37 ± 0.07 | 300 |
| Scar2-not loaded  | 1.08 ± 0.12 | 300 |
| Scar2-loaded      | 1.34 ± 0.17 | 300 |
| Scar4-not loaded  | 1.34 ± 0.17 | 300 |
| Scar4-loaded      | 2.93 ± 0.12 | 300 |
| Scar5-not loaded  | 1.95 ± 0.08 | 300 |
| Scar5-loaded      | 1.71 ± 0.13 | 300 |
| Scar7-not loaded  | 1.95 ± 0.08 | 300 |
| Scar7-loaded      | 1.71 ± 0.13 | 300 |

The percentage of inhibition and ICP-MS were determined as the mean of two independent assays.

FIGURE 3 | Profile of time-plasma concentration of SCAR 2-loaded NLS following a single administration via oral gavage at a dose of 300 mg/kg body
weight.

When comparing the compounds of Group 2 (SCAR4-loaded and SCAR7-loaded complexes), it was observed that SCAR4-loaded ([Ru(pic)(dpbb)(phen)]PF₆) was absorbed most efficiently by mice. It had a Cmax of 352.0 μg L⁻¹ 20 min after administration via oral gavage, whereas the Cmax for SCAR7-loaded ([Ru(pic)(dppe)(phen)]PF₆) was only 1.455 μg L⁻¹. The significant difference in concentration may be due to the presence of an extended/elongated carbon chain in the bis(diphenylphosphino)butane (dpbb) ligand present in SCAR4-loaded complex, compared to the bis (diphenylphosphino)ethane (dppe) ligand coordinated to SCAR7-loaded complex, which confers a higher lipophilicity to ([Ru(pic)(dpbb)(phen)]PF₆). Consequently, the sample had a much higher absorption. Our results demonstrate that the low surface-tension of the formulation resulted in improved solubility of SCARs-loaded complexes into the NLS and bioavailability, as compounds that were not loaded were not bioavailable (Lawrence and Rees, 2000).

In this study, we used nanotechnology methods and obtained promising results. However, the great difficulty is that there are no reports on NLS, Ru complexes, and bioavailability evaluation.
CONCLUSION

The results of in vitro assays of SCARs loaded into the NLS demonstrate that these compounds maintained anti-mycobacterial activity against both sensitive strains and clinical isolates, compared to compounds that were not loaded into the formulation. The loaded compounds also reduced toxicity to the macrophage cell line. The SCARs loaded into the NLS showed intra-macrophagic activity in a concentration-dependent manner, with the exception of SCARs-loaded complex. Furthermore, it was possible to determine Cmax times for the SCARs loaded in the NLS following administration via oral gavage. Our results demonstrate that the compounds become bioavailable when using nanotechnology as a tool.

AUTHOR CONTRIBUTIONS

PBS developed the nanostructure, analyzed the cytotoxicity, performed the in vivo oral bioavailability assay, quantified the Ru concentrations in plasma, and assisted in drafting the paper. EF

REFERENCES

Aguaiar, I. D., Tavares, A., Roveda, A. C. Jr., Da Silva, A. C., Marino, L. B., Lopes, E. O., et al. (2015). Antitubercular activity of Ru(II) ionized complexes. Eur. J. Pharm. Sci. 70, 45–54. doi: 10.1016/j.ejps.2015.01.008

Allardyce, B. C. S., and Dyson, P. J. (2001). Ruthenium in medicine: current clinical uses and future prospects. Platin. Met. Rev. 45, 62–69.

Barbosa, M. I. F., Corrêa, R. S., Pozzi, L. V., de O. Lopes, E., Pavan, F. R., Leite, C. Q. F., et al. (2015). Ruthenium(II) complexes with hydroxypropidino carbamates: screening potential metallo drugs against Mycobacterium tuberculosis. Polyhedron 85, 376–382.

Batista, B. L., Rodrigues, J. L., Nunes, J. A., de Oliveira Souza, V. C., and Barbosa, F. (2009). Exploiting dynamic reaction cell inductively coupled plasma mass spectrometry (DRC-ICP-MS) for sequential determination of trace elements in blood using a dilute-and-shoot procedure. Anal. Chim. Acta 639, 13–18. doi: 10.1016/j.aca.2009.03.016

Bhat, Z. S., Rather, M. A., Maqbool, M., Lah, H. U., Yousuf, S. K., and Ahmad, Z. (2017). Cell wall: a versatile fountain of drug targets in Mycobacterium tuberculosis. Biomed. Pharmacother. 95, 1520–1534. doi: 10.1016/j.biopha.2017.09.036

Bruxel, F., Laux, M., Wild, L. B., Fraga, M., Koester, L. S., and Teixeira, H. F. (2012). Nanoemulsões como sistemas de liberação parenteral de fármacos. Quim. Nova 35, 1827–1840.

Collins, L. A., and Franzblau, S. G. (1997). Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 41, 1004–1009.

da Silva, P. B., de Souza, P. C., Calixto, G. M. F., de O. Lopes, E., Frem, R. C. G., Netto, A. V. G., et al. (2016). In vitro activity of copper(II) complexes, loaded or unloaded into a nanostructured lipid system, against Mycobacterium tuberculosis. Int. J. Mol. Sci. 17:745. doi: 10.3390/ijms17050745

De Freitas, E. S., Da Silva, P. B., Chorilli, M., Batista, A. A., De Oliveira Lopes, E., and Da Silva, M. (2014). Nanostructured lipid systems as a strategy to improve the in vitro cytotoxicity of ruthenium(II) compounds. Molecules 19, 5999–6008. doi: 10.3390/molecules19055999

Do Nascimento, F. B., Von Poelhsitz, G., Pavan, F. R., Sato, D. N., Leite, C. Q. F., Selstrøe-araujo, H. S., et al. (2008). Synthesis, characterization, X-ray structure and in vitro antimycobacterial and antitumoral activities of Ru(II) phosphate/dimine complexes containing the “SpyrnMe2” ligand, SpymMe2 = 4,6-dimethyl-2-mercaptopryrimidine. J. Inorg. Biochem. 102, 1783–1789. doi: 10.1016/j.inorgbio.2008.05.009

Dos Santos Fernandes, G. F., De Souza, P. C., Moreno-Viguri, E., Santanavez-Veliz, M., Pauchar, R., Pérez-Silanes, S., et al. (2017). Design, synthesis and characterization of N-oxide-containing heterocycles with in vivo sterilizing antituberculosis activity. J. Med. Chem. 60, 8647–8660. doi: 10.1021/acs.jmedchem.7b01332

Dos Santos Ramos, M. A., Da Silva, P. B., Spósito, L., De Toledo, L. G., Bonifácio, B. V., Rodero, C. F., et al. (2018). Nanotechnology-based drug delivery systems for control of microbial biofilms: a review. Int. J. Nanomed. 13, 1–35. doi: 10.2147/IJN.S146195

Formariz, T. P., Urban, M. C. C., Da Silva Júnior, A. A., Gremião, M. P. D., and Oliveira, A. G. de (2005). Microemulsões e fases líquidas cristalinas como sistemas de liberação de fármacos. Rev. Bras. Ciências Farm. 41, 301–313. doi: 10.1590/S1516-93322005000300003

Freitas, E. S. (2015). Nanoencapsulação De Compostos De Rutênio, Análise De Sua Antituberculosa E Antitumoral. Molecules 19, 5999–6008. doi: 10.3390/molecules19055999

Golde, W. T., Gollobin, P., and Rodriguez, L. L. (2005). A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab. Anim. 34, 39–43. doi: 10.1038/labani.1005-39

Gruppov, V., Johnson, C. M., Marietta, K. S., Scherman, H., Zink, E. E., Crick, D. C., et al. (2006). Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 50, 1245–1250. doi: 10.1128/AAC.50.4.1245-1250.2006

Ho, H.-O., Hsiao, C.-C., and Sheu, M.-T. (1996). Preparation of microemulsions for control of microbial biofilms: a review. J. Inorg. Biochem. 60, 7137–7141. doi: 10.1021/jf204078t

Hu, L., Jia, Y., Niu, F., Jia, Z., Yang, X., and Jiao, K. (2012). Preparation and enhancement of oral bioavailability of curcumin using microemulsions vehicle. AAPS PharmSciTech 13, E172–E177. doi: 10.1208/spt070377

MCS analyzed the cytotoxicity and intra-macrophagic activity of clinical isolates, compared to compounds that were not

analyzed the anti-Mycobacterium tuberculosis assay, performed the in vivo oral bioavailability assay, and assisted in drafting paper. MCS analyzed the cytotoxicity and intra-macrophagic assays and assisted in drafting the paper. PCS analyzed the cytotoxicity assay and assisted in drafting the paper. FMS and AB synthesized and characterized the complexes and assisted in drafting the paper. CE, AR, and AM quantified the Ru concentrations in plasma and assisted in drafting the paper. RC analyzed the anti-mycobacterial activity of clinical isolates and assisted in drafting the paper. MC supervised the first author (PBS), developed the nanostructure and drafting the paper. FP conceived of the project, and assisted in drafting the paper.

FUNDING

This research was funded by grant #2013/14957-5 and grant #2013/09265-7 São Paulo Research Foundation (FAPESP) by the Coordination for the Improvement of Higher Education Personnel (CAPES) together with the Post-Doctoral National Program (PNPD) and the authors thank UNESP for the data of the dissertation (Freitas, 2015).
Kumar, R., Kumar, S., and Sinha, V. R. (2015). Evaluation and optimization of water in oil microemulsion using ternary phase diagram and central composite design. J. Diapers. Sci. Technol. 37, 37–41. doi: 10.1080/01932691.2015.103831

Lawrence, M. J. (1996). Microemulsions as drug delivery vehicles. Curr. Opin. Colloid Interface Sci. 1, 826–832.

Lawrence, M. J., and Rees, G. D. (2000). Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 45, 89–121.

Mali, S. N., and Morbale, T. S. (2016). Totally drug-resistant tuberculosis (TDR-TB): an overview. Int. J. Res. Methodol. 1, 29–36.

Martincic, A., Milacic, R., Vidmar, J., Turel, I., Keppler, B. K., and Scancar, J. (2014). New method for the speciation of Ru-based chemotherapeutics in human serum by conjoint liquid chromatography on affinity and anion-exchange monolithic disks. J. Chromatogr. A 1371, 168–176. doi: 10.1016/j.chroma.2013.12.011

Miyata, M., Pavan, F. R., Sato, D. N., Marino, L. B., Hirata, M. H., Cardoso, R. F., et al. (2011). Drug resistance in Mycobacterium tuberculosis clinical isolates from Brazil: phenotypic and genotypic methods. Biomed. Pharmacother. 65, 456–459. doi: 10.1016/j.biopha.2011.04.021

Palomino, J., Martin, A., Camacho, M., Guerra, H., Swings, J., and Portaels, F. (2002). Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 46, 2720–2722. doi: 10.1128/AAC.46.8.2720

Pavan, F. R., Maia, P. I. D. S., Leite, S. R. A., Deflon, V. M., Batista, A. A., Sato, D. N., et al. (2010a). Thiosemicarbazones, semicarbazones, dithiocarbazates and hydrazide/hydrazones: anti-Mycobacterium tuberculosis activity and cytotoxicity. Eur. J. Med. Chem. 45, 1898–1905. doi: 10.1016/j.ejmech.2010.01.028

Pavan, F. R., Poelhsitz, V., Do Nascimento, F. B., Leite, S. R. A., Batista, A. A., Deflon, V. M., et al. (2010b). Ruthenium(II) phosphine/picolinate complexes as antimycobacterial agents. Eur. J. Med. Chem. 45, 598–601. doi: 10.1016/j.ejmech.2009.10.049

Pavan, F. R., Poelhsitz, G. V., Barbosa, M. I. F., Leite, S. R. A., Batista, A. A., Ellena, J., et al. (2011). Ruthenium(II) phosphine/diimine/picolinate complexes: inorganic compounds as agents against tuberculosis. Eur. J. Med. Chem. 46, 5099–5107. doi: 10.1016/j.ejmech.2011.08.023

Pavan, F. R., Poelhsitz, G. V., Cunha, L. V. P., Barbosa, M. I. F., Leite, S. R. A., Batista, A. A., et al. (2013). In vitro and in vivo activities of ruthenium (II) Phosphine/Diimine/ Picolinate complexes (SCAR) against Mycobacterium tuberculosis. PLoS One 8:e64242. doi: 10.1371/journal.pone.0064242

Sato, M. R., da Silva, P. B., de Souza, R. A., dos Santos, K. C., and Chorilli, M. (2015). Recent advances in nanoparticle carriers for coordination complexes. Curr. Top. Med. Chem. 15, 287–297. doi: 10.2174/1568026615666150108145614

Schweizer, Y. S., Dushkin, M. I., Vavilin, V. A., Melnikova, E. V., Khoschenko, O. M., Kozlov, V. A., et al. (2006). Novel conjugate of moxifloxacin and carboxymethylated glucan with enhanced activity against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 50, 1982–1988. doi: 10.1128/AAC.00362-05

Segura, D. F., Netto, A. V. G., Frem, R. C. G., Mauro, A. E., Da Silva, P. B., Fernandes, J. A., et al. (2014). Synthesis and biological evaluation of ternary silver compounds bearing N,N-chelating ligands and thiourea: x-ray structure of [(Ag(bpy)(µ-tu)) 2](NO3)2 (bpy = 2,2′-bipyridine; Tu = thiourea). Polyhedron 79, 197–206. doi: 10.1016/j.poly.2014.03.004

Senousy, B. E., Belal, S. L., and Draganov, P. V. (2010). Hepatotoxic effects of therapies for tuberculosis. Nat. Rev. Gastroenterol. Hepatol. 7, 543–556. doi: 10.1038/nrgastro.2010.134

Singh, M., Kanoui, J., Parashar, P., Arya, M., Tripathi, C. B., Sinha, V. R., et al. (2018). Augmented bioavailability of felodipine through an α-linolenic-acid-based microemulsion. Drug Deliv. Transl. Res. 8, 204–225. doi: 10.1007/s13346-017-0453-9

Vigano, L., Skerry, C., McCann, M., and Devereux, M. (2015). Tuberculosis: an inorganic medicinal chemistry perspective. Curr. Med. Chem. 22, 2199–2224. World Health Organization [WHO] (2017a). Global Tuberculosis Report 2017. Geneva: World Health Organization, 2017.

World Health Organization [WHO] (2017b). Tuberculosis. Geneva: World Health Organization, 2017.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 da Silva, de Freitas, Socia, de Souza, da Silva, Batista, Eismann, Rolisola, Menegário, Cardoso, Chorilli and Pavan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.